Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 288,214
  • Shares Outstanding, K 54,898
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,180 K
  • EBIT $ -41 M
  • EBITDA $ -40 M
  • 60-Month Beta -0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.53

Options Overview Details

View History
  • Implied Volatility 223.08% (+84.56%)
  • Historical Volatility 76.15%
  • IV Percentile 68%
  • IV Rank 16.54%
  • IV High 970.42% on 02/17/26
  • IV Low 74.98% on 07/30/25
  • Expected Move (DTE 20) 0.93 (17.65%)
  • Put/Call Vol Ratio 1.02
  • Today's Volume 178
  • Volume Avg (30-Day) 221
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 6,507
  • Open Int (30-Day) 4,587
  • Expected Range 4.32 to 6.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.25
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.76 +10.29%
on 02/24/26
6.14 -14.43%
on 01/28/26
-0.85 (-13.93%)
since 01/27/26
3-Month
4.38 +19.86%
on 12/02/25
6.82 -23.08%
on 12/11/25
+0.63 (+13.64%)
since 11/26/25
52-Week
4.25 +23.53%
on 04/09/25
9.13 -42.50%
on 03/03/25
-3.35 (-38.95%)
since 02/27/25

Most Recent Stories

More News
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 5.25 (+1.94%)
Candel Therapeutics Announces Pricing of Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 5.25 (+1.94%)
Candel Therapeutics Announces Proposed $100 Million Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 5.25 (+1.94%)
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate...

CADL : 5.25 (+1.94%)
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 5.25 (+1.94%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 5.25 (+1.94%)
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 5.25 (+1.94%)
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate...

TRIN : 14.79 (-2.70%)
CADL : 5.25 (+1.94%)
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3...

CADL : 5.25 (+1.94%)
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...

CADL : 5.25 (+1.94%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 5.80
2nd Resistance Point 5.67
1st Resistance Point 5.46
Last Price 5.25
1st Support Level 5.12
2nd Support Level 4.99
3rd Support Level 4.78

See More

52-Week High 9.13
Fibonacci 61.8% 7.27
Fibonacci 50% 6.69
Fibonacci 38.2% 6.11
Last Price 5.25
52-Week Low 4.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar